16 results about "Cell entry" patented technology

An immunotherapeutic protein and methods of use and production thereof are disclosed, wherein the immunotherapeutic protein comprises, for example, a cell surface receptor polypeptide which is a cellular entry receptor for the entry of a virus into a host cell, which is linked to a polypeptide comprising an Fc region component. When the cell surface receptor polypeptide is an angiotensin converting enzyme 2 (ACE2) polypeptide or a fragment thereof, the immunotherapeutic protein is capable of binding to a coronavirus spike protein (S protein) and may be useful as an antiviral agent for the prevention or treatment of a coronavirus infection. The Fc region component may comprise an amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG1 heavy chain polypeptide which may enable the production of soluble oligomeric forms or the assembly of oligomeric forms from soluble monomeric forms upon binding to an S protein of a coronavirus (i.e. as present on a virion or the surface of virus-infected cells).

The application discloses a Sting agonist liposome-warm sensitive gel, a preparation method and application thereof. The Sting agonist liposome-warm sensitive gel comprises a Sting agonist-loaded liposome and a warm sensitive gel, and the preparation method comprises the following steps: preparing the Sting agonist-loaded liposome, adding the warm sensitive gel into a prepared Sting agonist-loaded liposome solution, and stirring until completely dissolved, and the Sting agonist liposome-warm sensitive gel is obtained. The Sting agonist liposome-warm sensitive gel has the advantages of small liposome particle size, good stability, effectively improved cell entry and release behavior of the Sting agonist, avoided burst release effect, in-vivo continuous and stable stimulation of the Sting agonist, better drug efficacy, increased local drug concentration and reduced side effects; the gel matrix can protect the integrity of the liposome and improve the stability of the liposome. The advantages of the liposome and the gel are combined, the drug uptake into cells is increased, and good sustained and controlled release performance is achieved.

The invention discloses a method for solving the problem of lactic acid accumulation of senescent cells in the later culture period, which comprises the following steps of: adding nicotinamide into a culture system in the later culture period of fed-batch culture of mammalian cells to eliminate a lactic acid tail-raising state, so that lactic acid is continuously maintained in a low-level stable state; the lactic acid tail raising means that the concentration of lactic acid is increased again after cells enter a stable phase or a decline phase, and the total concentration of nicotinamide added in a culture system is 5 mM to 14 mM. According to the method, the lactic acid tail raising phenomenon in the later period of cell culture is precisely regulated and controlled, secondary accumulation of lactic acid of senescent cells is inhibited, the low lactic acid level is maintained, serious negative effects on cell growth and motility rate are avoided, the yield and quality stability of target protein are guaranteed, the process robustness is enhanced, the industrial amplification risk is reduced, and the method is suitable for industrial production. And a method library for regulating and controlling lactic acid in a protein biological medicine production process is enriched.

The present invention addresses the problem of providing a virus cell entry inhibitor that inhibits the entry of viruses into cells and makes it possible to prevent viral infections.　A virus cell entry inhibitor that solves the problem of the present invention is characterized by containing at least one selected from an eyebright extract, a kasoori methi extract, a Tartary buckwheat extract, an okra extract, a cinnamon extract, a berberry extract, and a shell ginger extract.

The invention relates to a mitochondrial delivery system and a preparation method and application thereof. According to the mitochondrial delivery system, safe and efficient cell entry of active mitochondria can be achieved, the mitochondrial delivery system has appropriate particle size and surface potential, toxicity to cells is avoided while the entrapment rate of the mitochondria is effectively improved and the electrochemical stability and biological activity of a mitochondrial membrane are guaranteed, and the mitochondrial cell entry efficiency is remarkably improved. The mitochondrial delivery system not only can transplant active mitochondria into common cells to repair cell damage, but also can transplant the active mitochondria into egg cells to play a role across a zona pellucida and a plasma membrane barrier. The mitochondrial delivery system can be used for treating mitochondrial diseases related to mitochondrial dysfunction, especially infertility caused by mitochondrial dysfunction of egg cells.

The invention discloses a high-light-resistant algal strain high-speed screening method and system based on micro-fluidic single cell sorting, and relates to the field of bioengineering.The high-light-resistant algal strain high-speed screening method comprises the steps that haematococcus free cells in the logarithmic phase are taken and added into a double-fluorescence probe mixed solution, and incubation is conducted in a dark place to obtain a haematococcus solution; bBM sheath fluid and haematococcus fluid are introduced into a sample introduction area of the micro-fluidic chip, the BBM sheath fluid and the haematococcus fluid are focused by the sample introduction area and then enter a highlight stress area, highlight treatment is carried out to induce motile cells to be transformed into spores, and the transformed cells enter a detection area. Through in-situ high light stress and single cell continuous sorting of the micro-fluidic chip, the sorting efficiency is high, and the screening period is greatly shortened; three parameters of chlorophyll fluorescence, astaxanthin fluorescence and forward scattering light are adopted for cooperative detection, and a threshold value which is quantitatively set based on a control group is combined, so that the proportion of a false positive strain is reduced to be less than 5%, and the screening accuracy of a double-superior strain is greatly improved; the microfluidic chip is extremely low in single reagent consumption, greatly reduces the screening cost of single strains, and is easy for large-scale popularization and application.

The present disclosure relates to systems, methods and compositions for decoding ligand- receptor interactions, for delivering nucleic acids and proteins into target cells and for performing single cell multiomics. Disclosed are engineered lentiviruses displaying ligands that deliver cargo into target cells upon cognate receptor-ligand interaction. Also disclosed are compositions and methods including pMHC or antigen epitopes displaying lentiviruses for identifying pMHC / T-cell receptors and antigen / B-cell receptor interactions.

The application provides a coordination nanometer assembly of a chiral cyclic peptide and a manganese ion, a preparation method and application thereof, the method of the application combines a manganese superoxide dismutase protein domain with a unique tumor microenvironment of a melanoma high tyrosinase, and first designs polypeptide sequences with different chirality L‑ Y D‑ h L‑ D D‑ h、 L‑ Y L‑ H L‑ D L‑ H and D‑ y D‑ h D‑ d D‑ h, regulates polypeptide chirality, improves in-vivo circulation stability and cell entry efficiency of the nanometer assembly, coordinates self-assembly of manganese and the chiral cyclic peptide, simulates in-situ oxidation of the tumor microenvironment for photothermal therapy, and coats cell membranes. The method of the application is simple, the experimental conditions are mild, and the method is easy to operate, the cell membrane coated nanometer assembly prepared by the method not only has long circulation stability and high cell entry efficiency, but also can realize mild photothermal therapy through in-situ oxidation, release manganese ions to activate the CGAS-STING pathway for tumor immunotherapy, and has potential application value in the field of tumor combination therapy.

The invention belongs to the technical field of biomedical materials, and particularly relates to a porous polyester microsphere filler for improving the volume and form of an external nose, which comprises degradable polyester polymer microspheres with porous structures; the porous structure is a penetrating type porous structure, and the porosity is 50%-90%; the particle size of the polymer microspheres is 100-500 [mu] m, and the polymer microspheres account for 1-60% of the mass of the filler; and a thickening agent, an excipient, a carrier, a medicine and nutritional ingredients, according to the invention, the porous microsphere filler has a rich microscopic hole structure, so that fixation on the nose of a human body is facilitated, and exposure and infection due to external force are avoided; meanwhile, the porous microspheres and the penetrating through hole structure in the porous polyester microsphere filler are beneficial to cell entry, a large volume and a large surface area are provided for transportation of nutrient substances / removal of wastes, adhesion, proliferation and differentiation of the cells are finally caused, a regenerated collagen net structure is finally formed, and a more natural repairing effect is achieved.

The invention discloses an application of 89Zr-labeled umbilical cord mesenchymal stem cells in preparation of a systemic sclerosis pharmacokinetic tracing reagent. The radiochemical purity of the radionuclide 89Zr-labeled umbilical cord mesenchymal stem cells is greater than or equal to 90%, the cell activity is greater than or equal to 90%, and the in-vitro 24-hour retention rate is greater than or equal to 85%. The in-vivo distribution rule of the human umbilical cord-derived mesenchymal stem cells is detected, and a relationship is established between dynamic distribution of the marker after the cells enter the body and the cell curative effect, so that the clinical curative effect of a cell drug is effectively improved, the risk is reduced, and the drug interaction is reduced. A visual and reliable technical means is provided for evaluating targeting and efficacy of stem cell treatment, and the method has important clinical research and transformation values.

The invention comprises a housing with a separation chamber. The separation chamber may comprise a first chamber, a second chamber and a membrane between the first chamber and the section chamber. The membrane prevents non-motile cells from a semen sample in the first chamber, and allows motile cells from the semen sample, to enter the second chamber. The housing has an inlet for the semen sample to enter the separation chamber and at least one outlet opening for extracting the motile cells from the separation chamber. A hollow interior of a straw is connected with the at least one outlet opening of the separation chamber of the housing. A fluid pressure difference extracts motile cells from the separation chamber to the hollow interior of the straw.

The application discloses a cervical cell seven-classification method and system based on hierarchical routing and boundary expert fusion, and belongs to the technical field of image processing. In order to solve the technical problem that the existing technology directly adopts a single multi-classification model for cell classification, resulting in unreliable gray area boundary discrimination and finally leading to unstable cell classification result discrimination, the application utilizes multi-dimensional morphological indexes and detection confidence to calculate quality points; single cells and cell groups and halo cells are shunted for processing, the cell groups and the halo cells are directly outputted in types, the single cells enter subsequent processes, different morphological cells are avoided from being mixed into the same classifier, the single model training target inconsistency and feature deviation problem is solved; the single cell five-classification basic probability is acquired firstly, target areas of ASC-US and LSIL and ASC-H and HSIL are screened out through boundary uncertainty comprehensive points and quality points, finally probability is obtained through fusion of morphological indexes, bias probability and fusion strength, and the class with the maximum probability is selected as the seven-classification result. The application is used for cervical cell classification.

This invention discloses a method for constructing an in vitro model of senescent astrocytes, belonging to the interdisciplinary fields of cell biology, neuroscience, and biomechanics. The method includes: isolating and culturing primary astrocytes; performing adherent cell culture on the obtained primary astrocytes; and applying a compressive stress of 3-10 kPa to the adherent astrocytes for induced culture to obtain a model of senescent astrocytes. By simulating the changes in the mechanical microenvironment during brain tissue aging, the model successfully induces astrocytes into a senescent state using continuous vertical compressive stress. The constructed model can be used to screen anti-aging drugs or drugs for treating neurodegenerative diseases.

The present invention relates to compositions, combinations and methods for the expression of a gene sequence of interest in a target cell wherein the composition comprises; (a) a first vector comprising a non-native receptor sequence, wherein the first vector is capable of introducing and / or expressing the non-native receptor sequence in the target cell, resulting in the exhibition of the non-native receptor on the target cell surface; and (b) a second vector comprising the gene sequence of interest wherein the second vector uses the non-native receptor for cell entry and enables the expression of the gene of interest in the target cell.

This invention discloses a method for preparing T cells for tumor therapy by reducing the content or activity of SARDH protein. The method for preparing T cells for tumor therapy includes: reducing the content or activity of SARDH protein in recipient T cells, or reducing the expression level of the SARDH gene in recipient T cells, or knocking out the SARDH gene in recipient T cells, to obtain target T cells for tumor therapy. This invention discovers a novel target with significant innovative mechanisms of action. By reducing the content or activity of SARDH protein, or reducing the expression level of its encoding gene, or knocking out its encoding gene, the efficacy of T cell immunotherapy can be further improved. This invention provides a new perspective on elucidating the mechanism by which T cells enter tumors and become exhausted.

Apparatus and methods are described, including placing an implantable frame (20) that comprises struts (98, 99) that define cells (93) into a delivery device (40), such as to cause the frame (20) to transition from a non-radially constrained configuration of the frame (20) to a radially constrained configuration of the frame (20), thereby causing at least a portion of the cells (93) to elongate and to curve circumferentially around a longitudinal axis of the frame (20), such that for each of the portion of the cells (93), a tip (94) of the cell (93) becomes circumferentially non-aligned with a base (96) of the cell (93). The implantable frame (40) is released from the delivery device (40) to thereby cause the frame (20) to transition from the radially constrained configuration of the frame (20) to the non-radially constrained configuration of the frame (20). Other applications are also described.